Targets › TAURINE
1 program from 1 company in 1 trial: 1 Phase 2; Immunology; next expected readout Dec 2026.
Open in Phaseline: the race on TAURINE, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Hospital de Clinicas de Porto Alegre | Taurine Semi-essential amino acid with antioxidant and osmoregulatory properties | TAURINE | Phase 2 | Diabetes Mellitus, Type 2 | Dec 2026 |
Diabetes Mellitus, Type 2 (1)
small molecule (1)
Hospital de Clinicas de Porto Alegre (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.